Market Overview:
Globally the Parkinson’s disease therapeutics market is increasing rapidly. The major factor that drives the growth of the Parkinson’s disease therapeutics market is the increasing growth in aging population. Furthermore, increasing environmental factors & genetic heredity is increasing the growth of the Parkinson’s disease therapeutics market.
Additionally, the Parkinson's Disease Therapies Market Share is growing due to rising environmental variables and genetic heredity. However, the risk of Parkinson's disease rises with age, and the disease occurs most frequently in people over 50.
Segmental Analysis:
Parkinson’s disease Therapeutics Market, by Treatment Type:
Medications
Dopamine Precursors
Peripheral Decarboxylase Inhibitors
COMT Inhibitors
MAO Inhibitors
Others
Surgical Therapy
Deep Brain Stimulation (DBS)
Carbidopa/Levodopa Enteral Suspension
Parkinson’s disease Therapeutics Market, by End-user:
Hospitals & Clinics
Academic & Industrial Research
Others
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1572
Detailed Regional Analysis
The regional review of the Parkinson's disease therapeutics market is segmented into Europe, Asia Pacific, the Americas, the Middle East and Africa. North America advances the Parkinson's disease treatments market, owing to improved healthcare expenditures that contribute to the region's market development. Europe is appraised to be in second place in the global market for Parkinson's disease medicines. The market in this area is driven by the collective government initiatives to improve healthcare manufacturing and the growing acceptance of research and development pursuits for chronic ailments in the healthcare domain. Due to the mounting number of healthcare bodies and the intensifying prevalence of Parkinson's condition, the Parkinson's disease therapeutics market in the Asia Pacific is projected to increase over the forecast period. The foremost market competitors in this region are India, China, and Japan, and the Asia Pacific region is likely to be the fastest-growing market for Parkinson's disease therapies.
Competitive Analysis:
- Salix Pharmaceuticals
- GlaxoSmithKline Plc
- Impax Laboratories, LLC
- Teva Pharmaceutical Industries Ltd
- Novartis AG, Orion Corporation
- Mylan N.V.
- Par Pharmaceutical
- Cipla Inc.
- Daiichi Sankyo
- Apotex Inc.
- Wockhardt Limited
The important contenders in the Parkinson's disease therapeutics market are GlaxoSmithKline Plc, Novartis AG, Impax Laboratories, LLC, Salix Pharmaceuticals, Apotex Inc., Teva Pharmaceutical Industries Ltd, Orion Corporation, Mylan N.V., Par Pharmaceutical, Cipla Inc., Daiichi Sankyo, and Wockhardt Limited.
Industry Updates:
Nov 2021 Gain Therapeutics, a biotechnology company specializing in discovering and developing therapies for neurodegenerative diseases, recently presented data from a study conducted at the University of Maryland School of Medicine. The study involved the evaluation of two lead structurally targeted allosteric regulators (STARs) compounds for treating Gaucher and GBA1 Parkinson's disease; according to the company, the results showed "highly statistically significant effects" on all measurable outcomes.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/parkinsons-disease-therapeutics-market-1572
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: [email protected]
Market Insights The global market for Parkinson's disease therapeutics is expected to grow significantly during the forecast period of 2017 to 2023 according to a new research report by Market Research Future (MRFR).
The lack of effective treatment options and the increasing occurrence of the disease has catapulted market growth as there is a high, unmet demand.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/1572Since the cause of this disease is widely suspected to be genetic; genomic treatment options are expected to gain traction in the coming years.
Collaborations between pharmaceutical companies and research facilities are expected to provide oppurtunites for growth.Market SegmentationSegmental evaluation of the market has been done in the report to allow an extensive view of the market and its various components.
The global Parkinson's disease therapeutics market has been segmented by diagnostics tests, drugs, and region.By diagnostic tests, the market has been segregated to include positron emission tomography (PET) scans, magnetic resonance imaging (MRI), and computed tomography (CT) scan.By drugs, the market has been divided into, Sinemet, dopamine agonists, Symmetrel, anticholinergics, Eldepryl and Azilect, COMT and others.By region, the global market has been divided into North America, Europe, the Asia-Pacific and the Middle East & Africa.Regional AnalysisNorth America and Europe have the two largest shares with North Ameria's market share being the most significant.
This is primarily due to the prevalence of Parkinson's disease in developed countries where there are high populations of geriatrics.
Increase in research funding and favorable insurance reimbursements for medical costs are expected to fuel market growth for these regions during the forecast period.Meanwhile, the Asia-Pacific is anticipated to grow at a steady CAGR during the forecast period.
Get the Best treatment of speech and language therapy for Parkinson’s disease, we provide the best speech and language to improve muscle weakness, voice, and reasonable problems for more detail call at (808) 887-0920 or visit our site
